-
Unity Biotechnology Inc NasdaqGS:UBX Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Location: 285 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://unitybiotechnology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
17.38M
Cash
16.93M
Avg Qtr Burn
-5.51M
Short % of Float
4.72%
Insider Ownership
1.90%
Institutional Own.
17.19%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic macular edema | Phase 2b Update | |
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic retinopathy , Diabetic macular edema, Age-related macular degeneration | Phase 2a Update |